190 related articles for article (PubMed ID: 9785336)
1. Prediction of response to treatment with recombinant human erythropoietin in anaemia associated with cancer.
Beguin Y
Med Oncol; 1998 Aug; 15 Suppl 1():S38-46. PubMed ID: 9785336
[TBL] [Abstract][Full Text] [Related]
2. Prediction of response to optimize outcome of treatment with erythropoietin.
Beguin Y
Semin Oncol; 1998 Jun; 25(3 Suppl 7):27-34. PubMed ID: 9671327
[TBL] [Abstract][Full Text] [Related]
3. Recombinant human erythropoietin in the treatment of cancer-related or chemotherapy-induced anaemia in patients with solid tumours.
Nowrousian MR
Med Oncol; 1998 Aug; 15 Suppl 1():S19-28. PubMed ID: 9785333
[TBL] [Abstract][Full Text] [Related]
4. [Tumor anemia. Overview of the role of human recombinant erythropoietin (r-hu-EPO) in treatment of tumor anemia].
Monnerat C; Leyvraz S
Praxis (Bern 1994); 1999 Jan; 88(5):178-88. PubMed ID: 10067375
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of erythroid marrow response to recombinant human erythropoietin in patients with cancer anaemia.
Ponchio L; Beguin Y; Farina G; Pedrazzoli P; Pedrotti C; Poggi G; Rosti V; Bergamaschi G; Battistel V; Cazzola M
Haematologica; 1992; 77(6):494-501. PubMed ID: 1289186
[TBL] [Abstract][Full Text] [Related]
6. Prediction of response and other improvements on the limitations of recombinant human erythropoietin therapy in anemic cancer patients.
Beguin Y
Haematologica; 2002 Nov; 87(11):1209-21. PubMed ID: 12414352
[TBL] [Abstract][Full Text] [Related]
7. Prediction of the responsiveness to treatment with erythropoiesis-stimulating factors: a prospective clinical study in patients with solid tumors.
Steinmetz T; Hellmich M; Neise M; Aldaud A; Lerchenmüller C; Tsamaloukas A; Fandel F; Weiligmann C; Totzke U; Schmitz S
Oncologist; 2007 Jun; 12(6):748-55. PubMed ID: 17602064
[TBL] [Abstract][Full Text] [Related]
8. Hypochromic erythrocytes (%): a reliable marker for recognizing iron-restricted erythropoiesis and predicting response to erythropoietin in anemic patients with myeloma and lymphoma.
Katodritou E; Terpos E; Zervas K; Speletas M; Kapetanos D; Kartsios C; Verrou E; Banti A; Effraimidou S; Christakis J
Ann Hematol; 2007 May; 86(5):369-76. PubMed ID: 17375302
[TBL] [Abstract][Full Text] [Related]
9. Erythropoietin and chronic lymphocytic leukemia.
Mauro FR; Gentile M; Foa R
Rev Clin Exp Hematol; 2002; Suppl 1():21-31. PubMed ID: 12735212
[TBL] [Abstract][Full Text] [Related]
10. The impact and management of anaemia in haematological malignancies.
Coiffier B
Med Oncol; 2000 Nov; 17 Suppl 1():S2-10. PubMed ID: 11188782
[TBL] [Abstract][Full Text] [Related]
11. Serum erythropoietin and creatinine concentrations as predictive factors for response to recombinant human erythropoietin treatment in anaemic tumour patients on chemotherapy.
Fjornes T; Wiedemann GJ; Sack K; Jelkmann W
Oncol Rep; 1998; 5(1):81-6. PubMed ID: 9458299
[TBL] [Abstract][Full Text] [Related]
12. rHuEpo for the treatment of anemia in myelofibrosis with myeloid metaplasia. Experience in 6 patients and meta-analytical approach.
Rodríguez JN; Martino ML; Diéguez JC; Prados D
Haematologica; 1998 Jul; 83(7):616-21. PubMed ID: 9718866
[TBL] [Abstract][Full Text] [Related]
13. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial.
Auerbach M; Ballard H; Trout JR; McIlwain M; Ackerman A; Bahrain H; Balan S; Barker L; Rana J
J Clin Oncol; 2004 Apr; 22(7):1301-7. PubMed ID: 15051778
[TBL] [Abstract][Full Text] [Related]
14. Response predicting factors to recombinant human erythropoietin in cancer patients undergoing platinum-based chemotherapy.
González-Barón M; Ordóñez A; Franquesa R; Constenla M; Montalar J; Gili F; Camps C; Sancho JF; Pérez-Cachot P
Cancer; 2002 Dec; 95(11):2408-13. PubMed ID: 12436449
[TBL] [Abstract][Full Text] [Related]
15. Supplemental Iron: A Key to Optimizing the Response of Cancer-Related Anemia to rHuEPO?
Henry DH
Oncologist; 1998; 3(4):275-278. PubMed ID: 10388116
[TBL] [Abstract][Full Text] [Related]
16. The role of recombinant human erythropoietin in the management of anaemic cancer patients: focus on haematological malignancies.
Osterbor A
Med Oncol; 2000 Nov; 17 Suppl 1():S17-22. PubMed ID: 11188781
[TBL] [Abstract][Full Text] [Related]
17. Correction of iron-deficient erythropoiesis in the treatment of anemia of chronic disease with recombinant human erythropoietin.
Arndt U; Kaltwasser JP; Gottschalk R; Hoelzer D; Möller B
Ann Hematol; 2005 Mar; 84(3):159-66. PubMed ID: 15565327
[TBL] [Abstract][Full Text] [Related]
18. Prediction of response to recombinant human erythropoietin (rHuEpo) in anemia of malignancy.
Cazzola M; Ponchio L; Pedrotti C; Farina G; Cerani P; Lucotti C; Novella A; Rovati A; Bergamaschi G; Beguin Y
Haematologica; 1996; 81(5):434-41. PubMed ID: 8952157
[TBL] [Abstract][Full Text] [Related]
19. Prediction of response to iron sucrose in inflammatory bowel disease-associated anemia.
Gasche C; Waldhoer T; Feichtenschlager T; Male C; Mayer A; Mittermaier C; Petritsch W;
Am J Gastroenterol; 2001 Aug; 96(8):2382-7. PubMed ID: 11513178
[TBL] [Abstract][Full Text] [Related]
20. Mature erythrocyte parameters as new markers of functional iron deficiency in haemodialysis: sensitivity and specificity.
Bovy C; Gothot A; Delanaye P; Warling X; Krzesinski JM; Beguin Y
Nephrol Dial Transplant; 2007 Apr; 22(4):1156-62. PubMed ID: 17237481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]